The Convention on Biological Diversity (CBD) in 1992 recognized the potential benefits of biotechnology but also the risks it poses to the environment and health. It established the need to regulate living modified organisms (LMOs) and set the stage for an international biosafety agreement. The Cartagena Protocol on Biosafety in 2000 provides a framework for countries to make informed decisions on imports of LMOs based on scientific risk assessments of their potential impacts on biodiversity and human health. It aims to ensure an adequate level of protection from risks while allowing for the benefits of biotechnology.
The Convention on Biological Diversity (CBD) in 1992 recognized the potential benefits of biotechnology but also the risks it poses to the environment and health. It established the need to regulate living modified organisms (LMOs) and set the stage for an international biosafety agreement. The Cartagena Protocol on Biosafety in 2000 provides a framework for countries to make informed decisions on imports of LMOs based on scientific risk assessments of their potential impacts on biodiversity and human health. It aims to ensure an adequate level of protection from risks while allowing for the benefits of biotechnology.
The Convention on Biological Diversity (CBD) in 1992 recognized the potential benefits of biotechnology but also the risks it poses to the environment and health. It established the need to regulate living modified organisms (LMOs) and set the stage for an international biosafety agreement. The Cartagena Protocol on Biosafety in 2000 provides a framework for countries to make informed decisions on imports of LMOs based on scientific risk assessments of their potential impacts on biodiversity and human health. It aims to ensure an adequate level of protection from risks while allowing for the benefits of biotechnology.
The Convention on Biological Diversity (CBD) in 1992 recognized the potential benefits of biotechnology but also the risks it poses to the environment and health. It established the need to regulate living modified organisms (LMOs) and set the stage for an international biosafety agreement. The Cartagena Protocol on Biosafety in 2000 provides a framework for countries to make informed decisions on imports of LMOs based on scientific risk assessments of their potential impacts on biodiversity and human health. It aims to ensure an adequate level of protection from risks while allowing for the benefits of biotechnology.
protect human and animal health and environment from the possible adverse effects of the products of modern biotechnology Biosafety training material borrowed from Marcia Finucane and Brandy Nelson at the University of Kentucky . International Evolution Environmentalism emerged as a distinct development in the last forty years. Emergence of “pressure groups” in the sixties First Earth Day (1970) The United Nations Conference on the Human Environment and Development (1972) The Brundtland Report: our Common Future (1987) The Rio Earth Summit (1992) Convention on Biodiversity (CBD) [1992] Cartagena Protocol on Biosafety (CPB) [1993] Convention of Biodiversity (CBD) [1992] – Focus: conservation and sustainable use of biodiversity – Recognized the potential of modern biotechnology for human well being – Took cognizance that modern biotechnology could have serious effects on environment and health – Article 8(g) emphasized the need to regulate the risks associated with the use of LMOS. – Article 19(3) set the stage for a legally binding international instrument about biosafety. The Cartagena Protocol on Biosafety (CPB) Entered into force on 29th December 1993 Focus on transboundary movement of the LMOS. Seeks to lay down an internationally acceptable framework to provide for an adequate level of protection against the possible adverse affects of LMOS on biodiversity and human health. Status of Protocol
On 29 January 2000, the Conference of the Parties to the
Convention on Biological Diversity adopted a supplementary agreement to the Convention known as the Cartagena Protocol on Biosafety.
The Protocol entered into force on 11 September 2003, ninety
days after the deposit of the fiftieth instrument of ratification. Objective: • “The objective of the Protocol is to contribute to ensuring an adequate level of protection in the field of the safe transfer, handling and use of living modified organisms resulting from modern biotechnology that may have adverse effects on the conservation and sustainable use of biological diversity, taking also into account risks to human health, and specifically focusing on transboundary movements". Features:
• Decision to accept import of GMOs on the basis of risk assessment
– to identify and evaluate the potential adverse effects that a GMO may have on the conservation and sustainable use of biodiversity in the receiving environments – to be undertaken in a scientific manner using recognized risk assessment techniques – country considering permitting the import of a GMO is responsible for ensuring that a risk assessment is carried out – it has the right to require the exporter to do the work or to bear the cost Features contd… • No technology or human activity is completely risk-free. People accept new technologies because they believe the potential benefits outweigh the potential risks
• The Protocol requires each country to manage
and control any risks they may be identified by a risk assessment • Effective risk management: – Monitoring systems, research programs, technical training and improved domestic coordination amongst government agencies and services
– Protocol also requires each government to notify
and consult other affected or potentially affected governments when it becomes aware that GMOs under its jurisdiction may cross international borders due to illegal trade or release into the environment THANK YOU